Prof. Matti Osmo Antero Lehtinen

University of Tampere, School of Health Sciences, Finland

E-mail: matti.lehtinen@uta.fi

Qualifications

Professorship qualification: virology (-90), epidemiol.(-04), public health (-10), University of Tampere

1995 Docent (adjunct professor) in virology, University of Oulu

1987 Docent (adjunct professor) in virology, University of Tampere

1985 M.D., Ph.D., (University of Tampere)

1983 M.D., (University of Tampere)

Publications (Selected)

1. Lehtinen, M., Gray, P., Luostarinen, T., Eriksson, T., Apter, D., Bly, A., ... & Dillner, J. (2024). Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ—population-based follow-up of two cluster-randomized trials. Frontiers in Cellular and Infection Microbiology, 14, 1437704.
2. Gray, P., Mariz, F. C., Eklund, C., Eriksson, T., Faust, H., Kann, H., ... & Lehtinen, M. (2024). Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study. npj Vaccines, 9(1), 146.
3. Adhikari, I., Eriksson, T., Harjula, K., Hokkanen, M., Apter, D., Nieminen, P., ... & Lehtinen, M. (2022). Association of Chlamydia trachomatis infection with cervical atypia in adolescent women with short-term or long-term use of oral contraceptives: a longitudinal study in HPV vaccinated women. BMJ open, 12(6), e056824.
4. Lehtinen, M., Lagheden, C., Luostarinen, T., Eriksson, T., Apter, D., Bly, A., ... & Dillner, J. (2021). Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial. BMJ open, 11(12), e050669.
5. Lehtinen, M., Apter, D., Eriksson, T., Harjula, K., Hokkanen, M., Natunen, K., ... & Struyf, F. (2021). Effectiveness of various human papillomavirus vaccination strategies: A community randomized trial in Finland. Cancer medicine, 10(21), 7759-7771.
6. Mariz, F. C., Gray, P., Bender, N., Eriksson, T., Kann, H., Apter, D., ... & Lehtinen, M. (2021). Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials. The Lancet Infectious Diseases, 21(10), 1458-1468.
7. Man, I., Vänskä, S., Lehtinen, M., & Bogaards, J. A. (2021). Human papillomavirus genotype replacement: still too early to tell?. The Journal of infectious diseases, 224(3), 481-491.
8. Gray, P., Kann, H., Pimenoff, V. N., Eriksson, T., Luostarinen, T., Vänskä, S., ... & Lehtinen, M. (2021). Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial. PLoS medicine, 18(6), e1003588.
9. Kann, H., Lehtinen, M., Eriksson, T., Surcel, H. M., Dillner, J., & Faust, H. (2021). Sustained cross-reactive antibody responses after human papillomavirus vaccinations: up to 12 years follow-up in the Finnish Maternity Cohort. The Journal of Infectious Diseases, 223(11), 1992-2000.
10. Tota, J. E., Struyf, F., Hildesheim, A., Gonzalez, P., Ryser, M., Herrero, R., ... & Sampson, J. N. (2021). Efficacy of AS04-adjuvanted vaccine against human papillomavirus (HPV) types 16 and 18 in clearing incident HPV infections: pooled analysis of data from the Costa Rica vaccine trial and the PATRICIA study. The Journal of infectious diseases, 223(9), 1576-1581.
11. Tota, J. E., Struyf, F., Hildesheim, A., Gonzalez, P., Ryser, M., Herrero, R., ... & Sampson, J. N. (2021). Efficacy of AS04-adjuvanted vaccine against human papillomavirus (HPV) types 16 and 18 in clearing incident HPV infections: pooled analysis of data from the Costa Rica vaccine trial and the PATRICIA study. The Journal of infectious diseases, 223(9), 1576-1581.
12. Robles, C., Bruni, L., Acera, A., Riera, J. C., Prats, L., Poljak, M., ... & Bosch, F. X. (2021). Determinants of human papillomavirus vaccine uptake by adult women attending cervical cancer screening in 9 European countries. American Journal of Preventive Medicine, 60(4), 478-487.
13. Lehtinen, T., Elfström, K. M., Mäkitie, A., Nygård, M., Vänskä, S., Pawlita, M., ... & Lehtinen, M. (2021). Elimination of HPV–associated oropharyngeal cancers in Nordic countries. Preventive medicine, 144, 106445.
14. Kalliala, I., Eriksson, T., Aro, K., Hokkanen, M., Lehtinen, M., Gissler, M., & Nieminen, P. (2021). Preterm birth rate after bivalent HPV vaccination: Registry-based follow-up of a randomized clinical trial. Preventive medicine, 146, 106473.
15. Vänskä, S., Luostarinen, T., Baussano, I., Apter, D., Eriksson, T., Natunen, K., ... & Lehtinen, M. (2020). Vaccination with moderate coverage eradicates oncogenic human papillomaviruses if a gender-neutral strategy is applied. The journal of infectious diseases, 222(6), 948-956.

Profile Details

WoS ResearcherID: GDE-1265-2022

https://orcid.org/0000-0002-9481-0535

https://www.researchgate.net/scientific-contributions/Matti-Lehtinen-39696707